15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
The Catholic University of Korea
Bioactive benzofuran derivatives: moracins A-Z in medicinal chemistry.
Dongguk University-Seoul
Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors.
Aurigene Discovery Technologies
Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus.
Stony Brook University
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
Mutabilis
Phellinstatin, a new inhibitor of enoyl-ACP reductase produced by the medicinal fungus Phellinus linteus.
Korea Research Institute of Bioscience and Biotechnology
Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).
Affinium Pharmaceuticals
A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
Novalex Therapeutics
Azetidine based transition state analogue inhibitors of N-ribosyl hydrolases and phosphorylases.
Industrial Research
Targeting plague virulence factors: a combined machine learning method and multiple conformational virtual screening for the discovery of Yersinia protein kinase A inhibitors.
The Rockefeller University
Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase.
University of California Irvine
Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties.
Astrazeneca